Overview

* 908 Devices ( MASS ) Q2 revenue grows 14% yr/yr, beating analyst expectations

* Company raises 2025 revenue outlook, indicating confidence in future growth

* Net loss of $13.3 mln in Q2, following restructuring and strategic acquisitions

Outlook

* 908 Devices ( MASS ) raises 2025 revenue outlook to $54 mln-$56 mln, for 13%-17% growth

Result Drivers

* HANDHELD PRODUCT GROWTH - Revenue increase driven by growth in handheld product and service revenue

* DEVICE LAUNCHES - Record placements of XplorIR and launch of VipIR contributed to revenue growth

* RESTRUCTURING IMPACT - Manufacturing consolidation and restructuring efforts strengthened financial profile

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $13 mln $12.20

Revenue mln (4

Analysts

)

Q2 EPS -$0.37

Q2 Net Miss -$13.30 -$5.79

Income mln mln (3

Analysts

)

Q2 Gross $6.40

Profit mln

Q2 $21.50

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for 908 Devices Inc ( MASS ) is $6.50, about 0.3% below its August 4 closing price of $6.52

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)